Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- HIF-PH Med Roxadustat Gets EU Panel Backing: Astellas/FibroGen
June 29, 2021
- Kaken Files Japan NDA for Eschar Remover KMW-1
June 29, 2021
- Kissei Licenses Out South Korean Rights for Fostamatinib
June 29, 2021
- Novo’s Smart Insulin Pens Get Japan Approval, Launch in H1 2022
June 28, 2021
- Otsuka Seeks EU Nod for Lupus Nephritis Drug
June 28, 2021
- CellCept Gets Additional Nod for GVHD in HSCT: Chugai
June 28, 2021
- Sumitomo Dainippon Chief’s Pay Tops 100 Million Yen
June 28, 2021
- MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
- Biosimilar Momentum Unabated in Japan Even with Supply Concerns
June 25, 2021
- Japan Pharma Market Forecast to Decline through FY2025: IQVIA
June 25, 2021
- BAN2401 Gets FDA’s Breakthrough Therapy Tag: Eisai/Biogen
June 25, 2021
- Boehringer, Japan Cancer Foundation Join Hands for Oncology Research
June 24, 2021
- Shionogi President Earns 242 Million Yen in FY2020
June 24, 2021
- Daiichi Sankyo Chief Takes Home 170 Million Yen in FY2020: Securities Report
June 23, 2021
- Opdivo Expands Label for Combo Use with Avastin/Chemo in NSCLC
June 23, 2021
- Roche Diagnostics’ ALK CDx Ventana Approved for Alunbrig
June 23, 2021
- MSD Tops Foreign Pharma List in Japan in FY2020, but Big Players in a Melee
June 23, 2021
- FoundationOne OK’ed as a CDx for Opdivo/Keytruda’s MSI-High Use: Chugai
June 23, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…